Transfemoral implantation of CoreValve Evolut R in patient with functionally bicuspid aortic valve

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F17%3A00007694" target="_blank" >RIV/00023884:_____/17:00007694 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.crvasa.2017.01.020" target="_blank" >http://dx.doi.org/10.1016/j.crvasa.2017.01.020</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2017.01.020" target="_blank" >10.1016/j.crvasa.2017.01.020</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Transfemoral implantation of CoreValve Evolut R in patient with functionally bicuspid aortic valve

Popis výsledku v původním jazyce

Catheter based aortic valve replacement became largely adopted technique to treat patients with severe aortic stenosis in the setting of prohibitive risk and in high risk operation patients. Based on the positive clinical data from the Nordic Aortic Valve Intervention (NOTION) Trial [1] and from a subset analysis from the CoreValve U.S. High Risk Pivotal Trial Medtronic plc. announced CE mark for the self-expanding CoreValve (TM) Evolut (TM) R to obtain an expanded indication to treat aortic stenosis in patients who are at intermediate risk for open-heart surgery. Bicuspid aortic valve was deemed contraindicated for CoreValve implantation and nowadays is considered to be "off label" use even if multiple publications showed successful CoreValve implantation in patients with stenotic bicuspid aortic valve [2,3]. Current case report tackles preprocedural evaluation of stenotic aortic valve anatomy and together with the relevant pictures illustrates recapurability and repositionability of abovementioned TAVI system in patient with funcionally bicuspid severely stenotic aortic valve. (C) 2017 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.

Název v anglickém jazyce

Transfemoral implantation of CoreValve Evolut R in patient with functionally bicuspid aortic valve

Popis výsledku anglicky

Catheter based aortic valve replacement became largely adopted technique to treat patients with severe aortic stenosis in the setting of prohibitive risk and in high risk operation patients. Based on the positive clinical data from the Nordic Aortic Valve Intervention (NOTION) Trial [1] and from a subset analysis from the CoreValve U.S. High Risk Pivotal Trial Medtronic plc. announced CE mark for the self-expanding CoreValve (TM) Evolut (TM) R to obtain an expanded indication to treat aortic stenosis in patients who are at intermediate risk for open-heart surgery. Bicuspid aortic valve was deemed contraindicated for CoreValve implantation and nowadays is considered to be "off label" use even if multiple publications showed successful CoreValve implantation in patients with stenotic bicuspid aortic valve [2,3]. Current case report tackles preprocedural evaluation of stenotic aortic valve anatomy and together with the relevant pictures illustrates recapurability and repositionability of abovementioned TAVI system in patient with funcionally bicuspid severely stenotic aortic valve. (C) 2017 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

60-64

Kód UT WoS článku

000410029900011

EID výsledku v databázi Scopus

2-s2.0-85013354697